PD-L1Negative (Nomembranousstaining) GainorJFetal,JClinOncol33,2015(abstr8012) Ph3programwithAtezoin1LNSCLC IMpower150Atezo+Carbo+Pac Non-squamousAtezo+Carbo+Pac+Avastin2017(PFS) n1200Carbo+Pac+Avastin IMpower130Atezo+Carbo+Nab-pac Non-squamous2017(PFS) ...
We propose that PDL1 is upregulated within the tumor in response to immunotherapy, but can be blocked to restore effective anti-tumor immune responses.Joseph AntoniosHoracio SotoRobert HarrisDavid NathansonSam SadeghiBenjamin EllingsonLinda Liau
GC patients with high level PDL1 expression in tumor cells or in immune cells were both associated with better survival compared with those with negative expression (5-year OS, 61% vs. 48%, P = 0.000, and 55% vs. 45%, P < 0.0001, respectively). As con... 展开 关键词: gastric ...
The purpose of this study was to elucidate the regulation of programmed death ligand 1 (PDL1), lactate dehydrogenase A (LDHA) and miR-34a in triple negative breast cancer (TNBC) and to explore the function and mechanism of PDL1 and LDHA as competitive endogenous RNAs (ceRNAs) in TNBC via...
The interaction of programmed cell death 1 ligand 1 (PDL1) with its receptor programmed cell death 1 (PD1) inhibits T cell responses, and blockade of this interaction has proven to be an effective immunotherapy for several different cancers. PDL1 can be expressed on the surface of tumour cell...
WoodsDM, SodréAL, VillagraA, et al.HDAC inhibition upregulates PD-1 ligands in melanoma and augments immunotherapy with PD-1 blockade[J]．Cancer Immunol Res, 2015, 3(12): 1375-1385.DOI: 10.1158/2326-6066.Cir-15-0077-t.HoggSJ, VervoortSJ, DeswalS, et al.BET-bromodomain inhibitors ...
近日,南京医科大学殷咏梅、朱一超、丁军利等人与国内研究者合作,在Journal for ImmunoTherapy of Cancer期刊发表的研究成果显示,ARB类降压药竟然可能是“披甲冷肿瘤特攻”,即它们能够专门针对免疫浸润极差、且微环境中堆积大量胶原的难治性肿瘤,成功逆转肿瘤微环境的免疫抑制性,为免疫检查点抑制剂(ICB)起效创造有利条件[...
PD-L1/PDCD1LG1/CD274/B7-H1 (Cancer Immunotherapy Target) Antibody (29126-MSM2-P0) in ARRAY Analysis of Protein Array containing more than 19,000 full-length human proteins using PD-L1 Mouse Monoclonal Antibody (PDL1/2742). Z- and S- Score: The Z-s...
靶点 PDL1 作用机制 PDL1抑制剂(程序性死亡配体1抑制剂) 治疗领域 肿瘤消化系统疾病呼吸系统疾病+ [12] 在研适应症 子宫癌晚期子宫内膜癌复发性子宫内膜癌+ [159] 非在研适应症 急性髓性白血病肺腺癌晚期头颈癌+ [54] 原研机构 AstraZeneca UK Ltd. ...
Correction: Dual antibody-aided mesoporous nanoreactor for H2O2self-supplying chemodynamic therapy and checkpoint blockade immunotherapy in triple-negative... Triple-negative breast cancer (TNBC) represents a formidable challenge due to the absence of estrogen receptor (ER), progesterone receptor (PR), an...